Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
NY Attorney General settles with Emergent for $900,000 and charges former CEO with insider trading
January 21, 2026
News Alert
Federal prosecutors in Massachusetts charge New Jersey biostatistician with insider trading
January 19, 2026
News Alert
Former Doximity executive pleads guilty in the Southern District of New York for insider trading
January 13, 2026
News Alert